XOMA (NASDAQ:XOMA) Announces Quarterly Earnings Results

XOMA (NASDAQ:XOMA) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.17), Zacks reports. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The business had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.75 million.

XOMA Stock Performance

NASDAQ:XOMA opened at $20.89 on Wednesday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The company has a fifty day moving average of $24.64 and a two-hundred day moving average of $27.29. The stock has a market capitalization of $246.15 million, a PE ratio of -6.00 and a beta of 1.00. XOMA has a fifty-two week low of $19.92 and a fifty-two week high of $35.00.

Insiders Place Their Bets

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on XOMA. StockNews.com lowered shares of XOMA from a “hold” rating to a “sell” rating in a report on Tuesday, February 25th. HC Wainwright cut their target price on shares of XOMA from $123.00 to $104.00 and set a “buy” rating for the company in a report on Monday, February 3rd.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.